Trials / Completed
CompletedNCT00485017
Efficacy and Safety of THR-4109 in Obese Subjects
A Phase II Randomized, Double-Blind, Double-Dummy, Parallel Group, Placebo Controlled Study of THR-4109 in Obese Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- Theracos · Industry
- Sex
- All
- Age
- 30 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effect of THR-4109 on weight loss in obese subjects over a 24-week treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | THR-4109 | THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks |
| DRUG | Placebo | Oral capsules daily in a.m. and in p.m. for 24 weeks |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-06-12
- Last updated
- 2019-09-30
Locations
20 sites across 2 countries: Russia, Sweden
Source: ClinicalTrials.gov record NCT00485017. Inclusion in this directory is not an endorsement.